ArticleScientific reports2023

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.

Hidetaka Matsumoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.